For many rare disease patients, the wait for treatment and research advancements can feel like a never-ending process. This wait is made more complicated by COVID-19, which has caused barriers for both research options and people who want help managing their illness. Some research has halted during the pandemic.
Cure Rare Disease is one of the many research companies learning to adapt to COVID-19. Cure Rare Disease founder and president Richard Horgan and his team are researching custom therapeutics for Duchenne muscular dystrophy, a condition that Horgan’s brother Terry lives with. Duchenne muscular dystrophy (DMD) causes progressive muscle degeneration, which leads to muscle weakness and other health complications.
Horgan talked to The Mighty about the importance of rare disease research, changes that his company had to make during COVID-19 and his goals for Duchenne muscular dystrophy research.